FAS and leukemia: Cell death evasion and progressive accumulation of B cells are the major relevant events in CLL pathogenesis, so targeting apoptotic pathways triggered by CD95 (Fas/Apo-1) and TNF-related-apoptosis-inducing ligand (TRAIL)/Apo-2 death receptors (DRs) has been suggested as novel therapeutic approaches to treat this leukaemia (Pleyer et al, 2009).